CAR-T news - the latest biotech news from Labiotech.eu

Home CAR-T Page 12

Latest Posts

xCelligence ols biosciences car t cancer cytotoxicity assay

News and Trends 12 Apr 2016

How CAR-T Cells Kill Cancer: Pictures start Moving

CAR-T is a groundbreaking personalized cancer therapy with tremendous potential to drive the patient’s own immune cells to specifically target and kill cancer cells. Because the development of this therapy is still in the early phase, new tools are needed to provide a quick potency assay to assess the cytotoxicity of the therapeutic T-cells prior […]

April 12, 2016 - 6 minutesmins - By Jerome Topsent

autolus ucl car t series b fundraising

News and Trends 21 Mar 2016

CAR-T Startup Gets €51M from Top&New Investors

Autolus (UK) has secured over €51M in a recent series B round, led by the biggest Biotech VC in Europe – and a new player in life science investment. Autolus is a 1-year-old spin-off of the University College London (UCL) focusing on the development of next-generation CAR-T therapies, addressing current limitations of this ‘wonder therapy‘. […]

March 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

gsk miltenyi biotech gmp cell gene therapy tcr car t

News and Trends 17 Mar 2016

GSK partners to Scale Manufacturing of CAR-T Therapies

Production of CAR-T therapies seems to be one of the biggest challenge of this promising technology. Miltenyi Biotec (Germany) and GSK have entered a new partnership to combine the clinical development of cell and gene therapies with manufacturing expertise. Milteniy is a German company of 1600 employees developing products for biomedical research and cellular therapy. It’s not the first […]

March 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

cancer top 8 biotech immunooncology europe oncology

News and Trends 7 Mar 2016

Infographic: The Top 8 Deadliest Cancers and Who in Biotech is Fighting Them

With more than 200 types of cancer, the possibility of developing a Universal Cure is in reality, a myth. However, the fight against the World’s Deadliest Cancers is far from being lost… Simply by having a quick look through our articles, we can easily confirm that cancer is one of the World’s main concerns in […]

March 7, 2016 - 2 minutesmins - By Dani Bancroft

DIRK BUSCH TECHNICAL UNIVERSITY MUNICH car t leukemia all

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to select more potent T-cells and engineer a safety mechanism was announced at the annual meeting of the AAAS in Washington (US). CAR-T therapies are one of the ways […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

oxford biotech biomedica novartis car t cancer

News and Trends 1 Feb 2016

World CAR-T Leader Starts New Program with a UK Biotech

Pretty impressive CAR-T news coming from across the Channel… Oxford BioMedica just launched a second collaboration with Novartis, which has shown tremendous Phase II results – and the most advanced in CAR-T therapy in development so far (read our review on how CAR-T works and who else is working the field). This collaboration covers the […]

February 1, 2016 - 2 minutesmins - By Philip Hemme

ADVERTISEMENT

fantastic years biotech

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

cellectis ucart19 nature cancer car t cell leukemia crs cytokine

News and Trends 12 Jan 2016

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Cellectis researchers have managed to come up with a new CAR architecture with a small-molecule triggered ‘on-switch’, permitting better control and safety in CAR T-cell therapy, as published in Nature. As we discussed during our interview with Andre Choulika, CEO of Cellectis, last month, one major drawback to CAR-T treatment for cancer is the lack of […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

leukemia ucart19 cellectis cancer cart trial UK

News and Trends 4 Jan 2016

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

So it begins…dubbed the ‘Miracle Cure’ for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK. Just 2 days before Christmas, the French billion euro Biotech, Cellectis, submitted a clinical trial application to the Medicines & Healthcare products Regulatory Agency (MHRA). Specifically, the request was to approve initiation […]

January 4, 2016 - 2 minutesmins - By Dani Bancroft

leukemia cart novartis jpg

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

Andre Choulika Cellectis D Morganti C

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]

November 19, 2015 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT